The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Telemonitoring Study - for Chronic Myeloid Leukemia (CML)
Official Title: Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Nilotinib) Therapy
Study ID: NCT01490983
Brief Summary: This study is being conducted in a population of patients with chronic phase Chronic Myeloid Leukemia (CML) to learn more about how patients follow prescribed regimens for taking oral cancer drugs.
Detailed Description: This is a randomized, controlled pilot study to introduce eMedonline telemonitoring technology to CML patients taking Gleevec or Tasigna. eMedonline will be used to automatically collect time-dose specific medication data for individual patients, including dosing times, missed doses, adverse events and e-diary data. All data will be available to research staff for remote review via Web interface. Adverse events and non-adherence will prompt interventions including supportive care counseling.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
UNC Healthcare, Chapel Hill, North Carolina, United States
Rex Cancer Center, Raleigh, North Carolina, United States
Rex Cancer Center - Wakefield, Raleigh, North Carolina, United States
Name: Robert Wehbie, MD
Affiliation: Rex Cancer Center - Wakefield
Role: PRINCIPAL_INVESTIGATOR